terbinafine: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
terbinafine: clinical details
Prescribing considerations
- Confirm that the presentation is compatible with a dermatophyte infection; reassess if it worsens or fails to improve.
- Use cautiously on markedly inflamed lesions or sensitive areas such as the face because the gel contains ethanol.
- Avoid ocular and mucosal exposure.
- The selected product is not recommended below 16 years because experience is limited.
Contraindications and cautions
- Hypersensitivity to terbinafine or any gel excipient.
Monitoring
- Routine systemic laboratory monitoring is not specified for this topical product.
- Monitor for local irritation, contact dermatitis, hypersensitivity or aggravation of the underlying condition.
Clinical pharmacology
Terbinafine inhibits fungal squalene epoxidase, causing ergosterol deficiency and intracellular squalene accumulation. Less than 5% is absorbed after topical application, so systemic exposure is very low.
Formulation and product differences
- The selected cutaneous gel contains ethanol, benzyl alcohol and butylated hydroxytoluene, which may contribute to local irritation.
- Instructions, excipients and licensing are product-specific and should not be extrapolated to creams, sprays, solutions or tablets.
terbinafine preparations and strengths
Gel
Route: Cutaneous
Strengths: 1%
terbinafine interactions
Systemic interactions are unlikely with topical terbinafine, but products applied to the same skin area require caution.
Other topical medicines
No interactions are known for the selected gel, but other medicinal products should not be applied to the treated area as a precaution.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.